1. Home
  2. SKYE vs CIX Comparison

SKYE vs CIX Comparison

Compare SKYE & CIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • CIX
  • Stock Information
  • Founded
  • SKYE 2012
  • CIX 1993
  • Country
  • SKYE United States
  • CIX United States
  • Employees
  • SKYE N/A
  • CIX N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • CIX Industrial Machinery/Components
  • Sector
  • SKYE Health Care
  • CIX Consumer Discretionary
  • Exchange
  • SKYE Nasdaq
  • CIX Nasdaq
  • Market Cap
  • SKYE 294.2M
  • CIX 294.2M
  • IPO Year
  • SKYE N/A
  • CIX 1998
  • Fundamental
  • Price
  • SKYE $6.57
  • CIX $23.49
  • Analyst Decision
  • SKYE Strong Buy
  • CIX
  • Analyst Count
  • SKYE 4
  • CIX 0
  • Target Price
  • SKYE $19.25
  • CIX N/A
  • AVG Volume (30 Days)
  • SKYE 408.4K
  • CIX 16.3K
  • Earning Date
  • SKYE 01-01-0001
  • CIX 07-30-2024
  • Dividend Yield
  • SKYE N/A
  • CIX 5.28%
  • EPS Growth
  • SKYE N/A
  • CIX N/A
  • EPS
  • SKYE N/A
  • CIX 1.66
  • Revenue
  • SKYE N/A
  • CIX $158,107,000.00
  • Revenue This Year
  • SKYE N/A
  • CIX N/A
  • Revenue Next Year
  • SKYE N/A
  • CIX N/A
  • P/E Ratio
  • SKYE N/A
  • CIX $14.33
  • Revenue Growth
  • SKYE N/A
  • CIX N/A
  • 52 Week Low
  • SKYE $1.44
  • CIX $17.39
  • 52 Week High
  • SKYE $19.41
  • CIX $39.91
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 46.65
  • CIX 42.52
  • Support Level
  • SKYE N/A
  • CIX $21.17
  • Resistance Level
  • SKYE $6.83
  • CIX $23.94
  • Average True Range (ATR)
  • SKYE 0.89
  • CIX 1.09
  • MACD
  • SKYE -0.18
  • CIX 0.06
  • Stochastic Oscillator
  • SKYE 76.30
  • CIX 25.94

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About CIX CompX International Inc.

Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.

Share on Social Networks: